Jeffrey Zwicker is a Hematology physician affiliated with Memorial Sloan Kettering Cancer Center. OpenAlex indexes 253 publications with 8,867 citations (h-index 44); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
530 E 74th St Rm 20-282
New York, NY 100213459
Telephone
646-608-2023Provider last certified this registry record 30 Nov 2022.
Clinical trials
- A Study of Isoquercetin in People With Ovarian Cancer
Sponsor: Memorial Sloan Kettering Cancer Center
- Isoquercetin in Sickle Cell Anemia
Sponsor: Jeffrey Zwicker, MD
- Study Of Weight-Based Versus Standard Dose Enoxaparin Thromboprophylaxis In High-Risk Hospitalized Cancer Patients
Sponsor: Dana-Farber Cancer Institute
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
13 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Regeneron Pharmaceuticals, Inc.Program year202513 payments$14,175openpaymentsdata.cms.gov ↗
- CSL BehringProgram year20251 payment
- Novartis Pharmaceuticals CorporationProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
100%Factor Xa inhibitor83.2%Eliquis75%Xarelto25%Part D<11 patientsLow Molecular Weight Heparin16.8%Enoxaparin Sodium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2025–2026 per NIH RePORTER. The latest:
- Isoquercetin as a PDI inhibitor: dose-optimization and patient phenotyping
Sloan-Kettering Inst Can Research
FY2026$612,382R01AT013147 - Isoquercetin as a PDI inhibitor: dose-optimization and patient phenotyping
Sloan-Kettering Inst Can Research
FY2025$631,382R01AT013147
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Management of chemotherapy-induced thrombocytopenia: guidance from the ISTH Subcommittee on Hemostasis and Malignancy
Journal of Thrombosis and Haemostasis
2023 - Artificial intelligence in the prediction of venous thromboembolism: A systematic review and pooled analysis
European Journal Of Haematology
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Valerie Rusch, MD
Memorial Sloan Kettering Cancer Center
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”